← Back to Search

Topical Gel

PR022 topical gel, 0.05% for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Realm Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 29 days
Awards & highlights

Study Summary

The purpose of this study is to determine whether PR022 Topical Gels are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~29 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 29 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent change from Baseline to Day 29 in Eczema Area and Severity Index (EASI)
Secondary outcome measures
Change from Baseline to Day 29 in 5 dimensions of itch (5-D Itch) scale
Change from Baseline to Day 29 in Dermatology Life Quality Index (DLQI)
Change from Baseline to Day 29 in SCORing Atopic Dermatitis (SCORAD)
+7 more
Other outcome measures
Body Weight Changes

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: PR022 topical gel, 0.1%Experimental Treatment1 Intervention
Applied twice daily for 28 days
Group II: PR022 topical gel, 0.05%Experimental Treatment1 Intervention
Applied twice daily for 28 days
Group III: PR022 topical gel vehiclePlacebo Group1 Intervention
Applied twice daily for 28 days

Find a Location

Who is running the clinical trial?

Realm Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
96 Total Patients Enrolled
Christian Peters, MD, PhDStudy DirectorRealm

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis
2017. "Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03351777.
All > Seborrheic Dermatitis > Atopic Dermatitis
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top